Please use this identifier to cite or link to this item:
Title: PiwiRNA-651 as marker of treatment response and survival in classical Hodgkin lymphoma.
Author: Cordeiro Santanach, Anna
Navarro Ponz, Alfons
Gaya, Anna
Díaz Beyá, Marina
Gonzalez Farré, Blanca
Castellano, Joan Josep
Fuster, Dolors
Martínez, Carmen
Martínez Pozo, Antonio
Monzó Planella, Mariano
Keywords: Malaltia de Hodgkin
Micro RNAs
Hodgkin's disease
Issue Date: 14-Jun-2016
Publisher: Impact Journals
Abstract: PiwiRNAs, small non-coding RNAs processed by Piwi proteins, are involved in maintaining genome stability in germline cells. Recently, piwiRNA expression has been identified in some tumors. We have examined the potential reactivation of the Piwi/piwiRNA pathway in classical Hodgkin lymphoma (cHL). We found that Piwi proteins and three selected piwiRNAs, including piR-651, were expressed in cHL patients and cell lines, indicating that the Piwi/piwiRNA pathway is active in cHL. Interestingly, low levels of piR-651 were associated with lack of complete response to first-line treatment, as well as shorter disease-free and overall survival in a cohort of 94 cHL patients. At diagnosis, piR-651 was underexpressed in cHL serum samples compared to healthy controls, while after complete remission, piR-651 levels increased to levels similar to healthy controls. This is the first evidence that piwiRNAs are active in tumor and serum samples and impact prognosis in cHL.
Note: Reproducció del document publicat a:
It is part of: Oncotarget, 2016, vol. 7, num. 29, p. 46002-46013
Related resource:
ISSN: 1949-2553
Appears in Collections:Articles publicats en revistes (Cirurgia i Especialitats Medicoquirúrgiques)
Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)

Files in This Item:
File Description SizeFormat 
663236.pdf4.32 MBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons